Department of Thoracic Medical Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People's Republic of China.
Department of General Medicine, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, People's Republic of China.
Medicine (Baltimore). 2023 Oct 6;102(40):e35423. doi: 10.1097/MD.0000000000035423.
Disulfidptosis is a novel form of metabolic-related regulated cell death (RCD) that is caused by disulfide stress caused by the accumulation of excess cystine in the cell. Targeting disulfide metabolism imbalance is an emerging strategy for the treatment of cancer. However, it is undetermined how disulfidptosis-related genes (DRGs) influence hepatocellular carcinoma (HCC). Unsupervised clustering analysis was performed on the TCGA-LIHC cohort to identify various phenotypes of disulfidptosis. GSVA was used to measure the activation of characteristic gene sets, while CIBERSORT was employed to estimate the infiltration of immune cells. Disulfidptosis-related signature was generated to quantify the phenotype of disulfidptosis in HCC patients. Next, we examined the disparities among the high and low disulfidptosis score categories by considering clinical characteristics, infiltration of immune cells, functions related to the immune system, sensitivity to chemotherapeutic drugs, and effectiveness of immunotherapy. Two different disulfidptosis phenotypes with different prognoses, clinical traits, biological pathways, and immune cell infiltration were identified. Based on differently expressed genes (DEGs) among 2 disulfidptosis phenotypes, a disulfidptosis-related signature was built. The prognostic value of this signature was then evaluated in the TCGA and GEO datasets. Low disulfidptosis score indicated favorable clinical outcomes, higher levels of immune cell infiltration, lower tumor purity, and enhanced immune responses. Furthermore, we noticed a clear disparity in tumor mutation load and drug responsiveness when comparing the high and low disulfidptosis score categories. Finally, a quantitative nomogram was built with disulfidptosis score and several clinical characteristics. The disulfidptosis-related signature provides new insights into the tumor immune microenvironment and complexity in HCC. The disulfidptosis score can serve as a promising tool for personalized prognostic prediction of HCC patients and for customizing more effective immunotherapeutic strategies.
二硫键蛋白病是一种新型的代谢相关调控细胞死亡(RCD)形式,由细胞内半胱氨酸积累引起的二硫键应激导致。靶向二硫键代谢失衡是治疗癌症的一种新兴策略。然而,尚不清楚二硫键蛋白病相关基因(DRGs)如何影响肝细胞癌(HCC)。对 TCGA-LIHC 队列进行无监督聚类分析,以确定二硫键蛋白病的各种表型。GSVA 用于测量特征基因集的激活,而 CIBERSORT 用于估计免疫细胞的浸润。生成二硫键蛋白病相关特征以量化 HCC 患者中二硫键蛋白病的表型。接下来,我们通过考虑临床特征、免疫细胞浸润、与免疫系统相关的功能、化疗药物敏感性和免疫治疗效果,检查高和低二硫键蛋白病评分类别之间的差异。确定了两种具有不同预后、临床特征、生物学途径和免疫细胞浸润的不同二硫键蛋白病表型。基于 2 种二硫键蛋白病表型之间的差异表达基因(DEGs),构建了二硫键蛋白病相关特征。然后在 TCGA 和 GEO 数据集评估该特征的预后价值。低二硫键蛋白病评分表明临床结局良好、免疫细胞浸润水平较高、肿瘤纯度较低且免疫反应增强。此外,当比较高和低二硫键蛋白病评分类别时,我们注意到肿瘤突变负荷和药物反应性存在明显差异。最后,构建了一个包含二硫键蛋白病评分和几个临床特征的定量列线图。二硫键蛋白病相关特征为 HCC 的肿瘤免疫微环境和复杂性提供了新的见解。二硫键蛋白病评分可以作为 HCC 患者个性化预后预测的有前途的工具,并为制定更有效的免疫治疗策略提供依据。